Editor’s Note Archive

Why are pharma companies in India still falling foul of overseas regulators?

AIDAN’s PIL accusing the DoP of 'browbeating' the NPPA might not be so far-fetched as innovators and generic companies cosy up…

Emerging market strategies of Big Pharma have been defined by two Ps: pricing and patents

Prime Minister Modi's first 100 days in office may not have quite met the expectations of India Pharma Inc but the cautious…

On August 6, the quality assurance (QA) division of the CDSCO had released guidelines on the procedures to be followed by its…

The fear of the Ebola Virus Disease (EVD) being imported into India is worrying our Parliamentarians but besides relying on…

India's drug pricing authority, the National Pharmaceutical Pricing Authority is once again at loggerheads with the industry

I had ended my last edit with the hope that this year, unlike previous years, the pharmaceutical sector’s hopes would not be as…

Narendra Modi's massive electoral mandate has unfortunately raised expectations; both from the man on the street as well as from…

Across industries, hopes are riding high on the Modi government